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Introduction {#sec1}
============

Antibiotic resistance is on the increase, exacerbated by the fact that, in recent years, only a few new compounds have reached the clinic. RNA polymerase (RNAP) is an essential enzyme accomplishing transcription in all living organisms. At the same time, the sequence divergence between bacterial and human RNAPs makes bacterial RNAP an excellent target for antibiotic development ([@bib19]). In the last few years, details of the mode of action of a number of inhibitors of RNAP have been described ([@bib8], [@bib13], [@bib28], [@bib30], [@bib33], [@bib49]). However, most of these molecules have limited clinical utility, mainly because of their poor penetration of the bacterial cell envelope or strong binding to human plasma protein. Nevertheless, the search for new molecules that target RNAP and analysis of their mode of action is a promising approach for the development of new antibiotics, as exemplified by the now clinically used fidaxomicin (trade name Dificid) for *Clostridium difficile-*associated diarrhea ([@bib44]).

The most studied class of antibiotics known to inhibit bacterial RNA transcription are the rifamycins, a family of mainly semisynthetic ansamycins derived from the natural product rifamycin S, of which rifampicin (RIF) is the most widely used ([@bib4]). RIF (and the other rifamycins) binds in a pocket (the RIF pocket) on the β subunit of RNAP in the vicinity of the catalytic site and sterically blocks propagation of the growing RNA chain through the main channel of RNAP ([@bib11], [@bib29]). The collision of RNA and RIF happens when the RNA reaches a length of 3--4 nucleotides, after which the RNA is released from the promoter complex as an abortive transcript. The length of the abortive RNA product can be influenced by the nature of the C3 substituent of the individual semisynthetic rifamycin. For example, rifabutin even inhibits synthesis of a trinucleotide (when reaction is started with a 5′-non-phosphorylated dinucleotide primer), whereas RIF still allows it ([@bib5]).

The rifamycins are used, as part of the current combination therapy, for the first-line treatment of tuberculosis (TB), the leading cause of death by infectious disease worldwide ([@bib47]), as well as treatment for non-tuberculous mycobacterial infections ([@bib40]). One of the major problems with known rifamycins is the rapid selection for mutations in the RIF-binding pocket of RNAP that lead to resistance. Multidrug-resistant strains of *Mycobacterium tuberculosis* (MDR-*M. tuberculosis*) present a major clinical problem because these strains are resistant to RIF in addition to isoniazid. In 2016, there were 600,000 new cases with resistance to RIF, of which 490,000 had MDR-TB. With a treatment success rate of only 54%, this highlights the requirement for improved treatment options. There are ∼100 different amino acid substitutions in the RIF pocket that have been found in RIF-resistant clinical isolates of *M. tuberculosis* ([@bib41]), with mutations at three positions of the RIF pocket that account for ∼70% of the total substitutions (D516, 7.4%; H526, 20%; S531, 42%; *E. coli* numbering).

Previous efforts to probe the structure-activity relationships of the rifamycins and, thus, to maximize their binding affinity for RNAP have shown that the minimum structural requirements essential for activity include two free hydroxyl groups at the C21 and C23 positions of the *ansa* chain and two polar (free hydroxyl or carbonyl) groups at the C1 and C8 positions of the napthoquinone ring. Furthermore the molecule must be able to adopt a specific conformational geometry to position these key functional groups in the correct spatial arrangement required for RNAP binding ([@bib6], [@bib26]). Thus, modification of the *ansa* bridge (e.g., hydrogenation or epoxidation of the C16,17 or C18,19 carbon-carbon double bonds) results in decreased binding to RNAP because of conformational changes in the molecule altering the spatial arrangement of the C1, C8, C21, and C23 functional groups, thus disrupting their critical hydrogen bonds with the RIF pocket ([@bib4], [@bib7]). Hence, the production of clinically used semisynthetic rifamycins (RIF, rifabutin, rifapentine, rifalazil, and rifaximin) has focused on the introduction of functionality at the C3 position to stabilize the oxidation state of the naphthoquinone core and to improve bioavailability ([@bib16], [@bib38]).

Here we isolated and, by using microbiological, biochemical, and structural biology techniques, studied an uncharacterized naturally produced antibiotic, kanglemycin A (KglA). KglA is an ansamycin antibiotic from the rifamycin family that displays two important and unusual *ansa* bridge modifications. We show that, despite having a mode of action similar to that of RIF, KglA has a larger binding surface with the RNAP provided by interactions of the *ansa*-bridge substituents and areas of RNAP that have not been previously accessible by rifamycin derivatives. As a result, KglA has an altered binding conformation compared with RIF, which makes it maintain higher activity against both RIF-resistant RNAPs and RIF-resistant bacteria.

Results {#sec2}
=======

Isolation of KglA {#sec2.1}
-----------------

Actinomycete bacteria have historically been an excellent source of bioactive compounds, particularly antibiotics. To identify new antibiotics targeting transcription, we screened a subset of strains from the Demuris collection of actinomycetes for their ability to inhibit cell growth and to inhibit cellular transcription. As a reporter strain, we used a previously described *B. subtilis* strain that has a *lacZ* gene fused to the promoter of the bacterial helicase *helD.* This promoter was selected as the one that is upregulated during the stress caused by partial inhibition of transcription in sub-inhibitory concentrations of an antibiotic ([@bib45]). In the disk assay shown in [Figure 1](#fig1){ref-type="fig"}A, when a paper disk soaked with antibiotic is placed on the X-gal-infused agar plate with a lawn of growing cells, this results in a colorimetric response at the edge of the zone of growth inhibition, observed as a blue halo ([Figure 1](#fig1){ref-type="fig"}A, left; compare the halos produced by RIF and carbenicillin, an inhibitor of cell wall synthesis). The isolate *Amycolatopsis* DEM30355 was of particular interest because it produced a compound (later identified as KglA, see below) that gave a blue halo at the edge of the zone of bacterial growth inhibition, indicative of transcription inhibition ([Figure 1](#fig1){ref-type="fig"}A, left). Importantly, in contrast to RIF, this new compound inhibited the RIF-resistant *B. subtilis* strain (βH482R; βH526R in *E. coli* numbering) ([Figure 1](#fig1){ref-type="fig"}A, right). We cultivated *Amycolatopsis* DEM30355 in a stirred tank bioreactor for 103.5 hr and extracted the secondary metabolites from the supernatant using Amberlite XAD-16 beads. Subsequent elution with methanol, extraction with ethyl acetate, and purification by multistep chromatography ([STAR Methods](#sec4){ref-type="sec"}) produced an orange crystalline compound that retained the observed biological activity against both the reporter and RIF-resistant strains ([Figure 1](#fig1){ref-type="fig"}A). Electrospray ionization-mass spectrometry (ESI-MS) revealed the mass, \[M+Na\]^+^ = 1004.3866 m/z ([Figure S1](#mmc1){ref-type="supplementary-material"}A), which corresponded to the mass of the previously described KglA. ^1^H and ^13^C nuclear magnetic resonance (NMR), extensive 2D NMR analysis, and, finally, single-crystal X-ray analysis ([Figures S1](#mmc1){ref-type="supplementary-material"}B--S1D; [Table S1](#mmc1){ref-type="supplementary-material"}) unambiguously confirmed the structure of the isolated compound to be KglA ([Figure 1](#fig1){ref-type="fig"}B).Figure 1Identification and Mode of Action of KglA(A) Disk diffusion assay with rifampicin (RIF), carbenicillin (Cb), and kanglemycin A (KglA). Paper disks soaked with antibiotics were placed on the lawns of wild-type *B. subtilis* carrying the *lacZ* gene under the *P*~*helD*~ promoter, inducible during partial inhibition of transcription (left), and RIF-resistant *B. subtilis* (right). Note the blue halo around the growth inhibition zones in the case of transcription inhibitors.(B) Chemical structure of KglA in comparison with RIF. The *ansa* chain modifications in KglA are highlighted. The semisynthetic group of RIF is shown in purple. See also [Figure S1](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.(C) Transcription *in vitro* by *E. coli* RNAP started with CpA on a linear template containing the T7A1 promoter. Runoff, termination, and abortive tri- and tetra-nucleotides are marked. Note that tetra-nucleotides migrate faster than tri-nucleotides under these electrophoretic conditions.(D) Different ratio of the di-nucleotide-long (pppApU) and the tri-nucleotide-long (pppApUpC) abortive products in the presence of RIF and KglA. Transcription was performed in the presence of the nucleotides depicted (in the absence of the CpA primer). Note that, in the 33% gel, runoff and termination products remain in the well.(E) The experiment was performed as in (D) but in the presence of AMP instead of ATP.(F and G) Inhibition of wild-type and RIF-resistant *E. coli* RNAPs by RIF and KglA. Error bars (F) are ± SD. The brackets (G) contain ± SE and the Hill slope.

KglA is an antibiotic originally isolated from the fermentation broth of *Nocardia mediterranei* var. *kanglensis* 1741-64 ([@bib46]), for which no mode of action has been previously proposed, and only limited information regarding its biological activity has been reported. It is an ansamycin antibiotic that shares similarities with rifamycins, albeit with a number of unusual structural features. Most notably, KglA differs from known rifamycins and their semisynthetic derivatives in that it contains two large *ansa* bridge substituents, a pendant 2,2-dimethyl succinic acid side chain at C20 and a unique sugar moiety (β-*O*-3,4-*O*,*O*'-methylene digitoxose) at C27 ([Figure 1](#fig1){ref-type="fig"}B). Furthermore, these modifications are unusual for bioactive natural and semisynthetic rifamycins, whose modifications are typically concentrated at the naphthoquinone core.

Mode of Action and Specificity of KglA {#sec2.2}
--------------------------------------

Activation of the *helD* promoter and its structural similarity to the rifamycins suggested that KglA targets bacterial RNAP. Therefore, we analyzed the effects of KglA on *in vitro* transcription by wild-type *E. coli* RNAP. KglA efficiently inhibited transcription on a linear DNA template containing the strong T7A1 promoter ([Figure 1](#fig1){ref-type="fig"}C). Inhibition of full-sized RNA products (run off or terminated) coincided with increased accumulation of short abortive tri- and tetra-nucleotide products ([Figure 1](#fig1){ref-type="fig"}C; the reactions were started with the dinucleotide primer CpA). Such a mode of action is characteristic of the rifamycins ([@bib12], [@bib29]), as can be seen from the pattern of inhibition of transcription by RIF ([Figure 1](#fig1){ref-type="fig"}C). In this mode of action, the antibiotic binds in the pathway of the nascent RNA, physically blocking its extension and inducing the release of short RNAs as abortive products.

Dinucleotide primer CpA that was used to start transcription does not carry a negatively charged triphosphate moiety at the 5′ end, which is present in NTPs used by RNAP *in vivo*. Therefore, we analyzed the effects of RIF and KglA in a native situation when transcription was started with ATP (in the absence of the CpA primer). As can be seen in [Figure 1](#fig1){ref-type="fig"}D, KglA completely blocked the formation of the triphosphorylated trinucleotide, pppApUpC, whereas RIF allowed some of its production (compare lanes 4, 5, and 6). Furthermore, KglA strongly diminished (70-fold inhibition) the formation of the first dinucleotide, pppApU, whereas RIF had only a moderate effect (3-fold inhibition) (compare lanes 7, 8, and 9). Next, to start the reaction, we used AMP, which lacks γ and β 5′ phosphates, present in ATP ([Figure 1](#fig1){ref-type="fig"}E). KglA only moderately inhibited formation of pApU (4-fold), suggesting that it is γ and, possibly, β phosphates at the 5′ end of the initiating nucleotide that clash with the additional groups of KglA (compare lanes 7, 8, and 9). However, the formation of trinucleotide pApUpC was still strongly inhibited by KglA compared with RIF ([Figure 1](#fig1){ref-type="fig"}E, lanes 4, 5, and 6). These results further suggest that extra groups and/or the mode of binding of KglA provide an additional steric and/or electrostatic (KglA has a negatively charged C20 2,2-dimethyl succinic acid side chain) hindrance for translocation of the 5′ phosphorylated dinucleotide RNA. Furthermore, KglA interference with the 5′ triphosphate moiety of the initiating nucleotide leads to inhibition even of the first phosphodiester bond formation (see structural support for these findings below).

The half maximal inhibitory concentration (IC~50~) values of KglA and RIF were similar against wild-type RNAP ([Figures 1](#fig1){ref-type="fig"}G and 1F). However, despite having a similar mode of action as RIF, we observed that KglA killed RIF-resistant bacteria (compare the inhibition zones in [Figure 1](#fig1){ref-type="fig"}A, right). To investigate this phenomenon, we prepared *E. coli* RNAPs carrying a series of RIF-resistant mutations, including βS531L, βD516V, βD516Y, βH526Y, βH526P, βH526R, and βI572F. These mutations correspond to the RIF resistance mutations in *M. tuberculosis* most frequently observed in clinical isolates, with βS531L, βD516V, and βH526Y accounting for 73% of all clinical RIF-resistant *M. tuberculosis* isolates ([@bib17]). Compared with RIF, KglA was much more potent against six of seven RIF-resistant RNAPs ([Figures 1](#fig1){ref-type="fig"}G and 1F); in particular, KglA was 10 times more active than RIF against the βS531L and βD516V mutants. Note that, although mutations at βH526 made RNAP insensitive to RIF (no inhibition at 2.5 mg/mL), KglA was still able to inhibit RNAPs with these mutations.

These results and *in vivo* data ([Figure 1](#fig1){ref-type="fig"}A) suggest that KglA binds to RNAP in the RIF-binding pocket of the β subunit but in a manner different from known rifamycins, resulting in an increased resilience to the RIF-resistant amino acid substitutions in the RIF-binding pocket of RNAP. Furthermore, the mode of action of KglA deviates from that of RIF because KglA more efficiently inhibits the early stages of RNA synthesis.

Structural Basis of RNAP Inhibition by KglA {#sec2.3}
-------------------------------------------

To reveal the basis of the KglA efficacy enhancement as induced by the modifications of the *ansa* bridge in comparison with rifamycin, we performed a crystallographic analysis of the complexes of KglA with RNAPs. To analyze the RNAP and KglA interaction on the atomic scale, a crystal of the *T. thermophilus* RNAP σ^A^ holoenzyme-*pyrG* promoter DNA complex ([@bib35]) was used to determine the X-ray crystal structure of the RNAP-KglA complex at 3.0-Å resolution ([Table 1](#tbl1){ref-type="table"}). Additionally, to understand the mechanism of inhibition of RIF-resistant RNAP by KglA, the crystal of the *E. coli* βS531L RNAP σ^70^ holoenzyme ([@bib31]) was used to determine the structure of the RNAP-KglA complex at 4.1-Å resolution ([Table 1](#tbl1){ref-type="table"}). The electron density maps of both RNAPs show unambiguous densities for the compound located in the RIF-binding pockets in the β subunits ([Figures 2](#fig2){ref-type="fig"}A and 2B). The binding modes of KglA to the RNAPs are almost identical; therefore, the atomic resolution structure of *T. thermophilus* RNAP-KglA was used for the precise modeling of KglA in complex with *E. coli* RNAP.Table 1Collection of Crystallographic Data and Refinement StatisticsComplex*Eco* RNAP -- KglA*Tth* RNAP -- KglAPDB code6CUX6CUU**Data Collection**Space groupP2~1~2~1~2~1~C2Cell dimensions *a* (Å)188.167185.221 *b* (Å)204.685101.315 *c* (Å)311.577294.279 β (°)9098.886Resolution (Å)50.0--4.150.0--3.0Total reflections608,898358,319Unique reflections93,684107,473Redundancy6.5 (6.2)3.3 (3.0)Completeness (%)[a](#tblfn1){ref-type="table-fn"}99.9 (100.0)99.7 (97.1)*I* / σ[a](#tblfn1){ref-type="table-fn"}16.2 (1.95)10.2 (1.14)*R*~sym~ (%)[a](#tblfn1){ref-type="table-fn"}7.7 (85.1)9.6 (61.4)CC^1/2^[a](#tblfn1){ref-type="table-fn"}(0.633)(0.629)**Refinement**Resolution (Å)45.03--4.146.3--3.0*R*~work~0.21000.2012*R*~free~0.25470.2483No. of atoms54,86728,254RMSDsBond length (Å)0.0130.006Bond angles (°)1.7761.089Clashscore11.475.84Ramachandran favored, %91.5797.64Ramachandran outliers, %0.940.35[^3][^4]Figure 2KglA Binding to Free and Promoter-Bound RNAP Holoenzyme(A) Overall views of *E. coli* (left) and *T. thermophilus* (right) RNAPs with KglA bound in the RIF-binding pocket. RNAPs (gray core and orange σ) and DNA (blue) are shown as ribbon models, and KglA (red) is shown as a stick model.(B) Electron density maps of KglA in complexes with *T. thermophilus* (top) and *E. coli* (bottom) RNAPs. Electron densities are shown as a light blue mesh, and KglA molecules are shown as stick models colored by element. The *ansa* bridge side chains of KglA extending from C20 and C27 are colored in yellow.(C) A close-up view of the RIF-binding pocket of the *T. thermophilus* RNAP containing KglA (in red, with the side chains in yellow). RNAP is shown as a transparent surface model (light blue), KglA is shown as a stick model with the *ansa* bridge side chains labeled, and the β subunit residues forming the RIF-binding pocket are shown as stick models. The hydrogen bonds between KglA and β amino acid residues (colored by element) are depicted by yellow dotted lines; the βR134 involved in polar interaction with the C20 sugar of KglA is shown in blue.(D) A side view of the RIF-binding pocket shown in (C). KglA is overlaid on RIF (gray); the side chains of the two molecules are labeled. KglA maintains a larger distance to the wall in the RIF-binding pocket than RIF.(E) Modeling of the initiating nucleotides in the active site of the *T. thermophilus* RNAP (from PDB: [4Q4Z](pdb:4Q4Z){#intref0100}) in the presence of KglA (left) and RIF (right). The ribonucleotides (red), the βQ567 and βH999 residues coordinating the 5′ end triphosphate (blue), and KglA and RIF (gray) are shown as stick and sphere models. The side chains of the inhibitors and the positions of the initiating NTPs are indicated. Red arrows indicate the translocation directions for the corresponding substrates.(F) Structural rearrangements in the RIF-binding pocket of *E. coli* βS531L RNAP triggered by KglA and RIF binding. RNAP is shown as a ribbon model in gray, the structured regions of the fork loop2 are shown in green, and the β531L residue (blue), KglA (colored by element with yellow side chains), and RIF (colored by element) are shown as stick and sphere models. The side chains of KglA and RIF are indicated. Arrows mark the clash points between the naphthalene cores of the corresponding compounds with the β531L side chain.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

The binding mode of KglA is similar to that of RIF and involves the formation of hydrogen bonds with the same amino acid residues of the RIF-binding pocket, including βQ393, βS411, and βR420 (side chain) and βF394 (main chain) ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}A; the numbering is for *T. thermophilus*; see [Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D for the corresponding amino acid residues in *E. coli* and *M. tuberculosis* RNAPs). Because of a different topology of the *ansa* bridge of KglA ([Figure S2](#mmc1){ref-type="supplementary-material"}B), the C23 hydroxyl group does not form an additional hydrogen bond with βF394, as observed in the *T. thermophilus* RNAP-RIF complex. However, the C27 β-*O*-3,4-*O*,*O*'-methylene digitoxose side chain establishes a hydrogen bond with the side chain of βR134 ([Figure 2](#fig2){ref-type="fig"}C). This KglA *ansa* bridge side chain inserts into a shallow pocket in the RIF-binding site and establishes additional non-polar interactions with the surrounding residues, significantly increasing the binding surface of KglA compared with RIF ([Figure 2](#fig2){ref-type="fig"}C). One of the structural consequences of the sugar side chain accommodation in the RIF-binding pocket is a rotational shift of KglA that increases the distance between the naphthalene core and the binding surface of the pocket compared with RIF ([Figure 2](#fig2){ref-type="fig"}D).

To validate the new interaction of the C27 β-*O*-3,4-*O*,*O*'-methylene digitoxose side chain with βR134, we constructed an *E. coli* RNAP carrying a mutation at the corresponding amino acid residue, βR143A. The mutation had little effect on RIF sensitivity ([Figure S2](#mmc1){ref-type="supplementary-material"}E, left). However, KglA was at least an order of magnitude less effective against βR143A RNAP than against wild-type RNAP, indicating the importance of this interaction for KglA binding ([Figure S2](#mmc1){ref-type="supplementary-material"}E, center). The IC~50~ of KglA for βR143A RNAP was still lower than for any RIF-resistant mutant RNAP, indicating that interactions of KglA within the rest of the RIF-binding pocket were still critical for its binding. Only a double mutation, βR143A/S531L, led to KglA resistance ([Figure S2](#mmc1){ref-type="supplementary-material"}E, right).

The presence of additional bulky side chains on the *ansa* bridge of KglA has an effect on the mechanism of *de novo* transcription initiation. Ansamycin binding in the RIF-binding pocket inhibits transcription by clashing with the 5′ end of a nascent RNA. Modeling shows that, in the *T. thermophilus* RNAP-RIF complex, the triphosphate moiety of the initiating nucleoside triphosphate (NTP) guided by hydrogen bonds with side chains of two essential residues, βQ567 and βH999 ([@bib9]), moderately clashes with the C3 side chain of RIF ([Figure 2](#fig2){ref-type="fig"}E, right). This clash does not strongly affect the formation of the first phosphodiester bond, likely because of flexibility of the C3 side chain. Even in the presence of RIF, there is an empty space (triphosphate retreat zone) that allows for accommodation of the 5′ triphosphate group followed by an extension of the nascent RNA to 3-mer ([@bib29]) before a severe clash with the +1 NTP inhibits further primer extension ([Figure 2](#fig2){ref-type="fig"}E, right). In contrast, the positional shift of KglA and the orientation of the negatively charged C20 2,2-dimethyl succinic acid side chain not only do not leave space for accommodation of the 5′ triphosphate group but also interfere with the correct placement of the initiating NTPs ([Figure 2](#fig2){ref-type="fig"}E, left), which explains the strong inhibition of the initial dinucleotide synthesis ([Figure 1](#fig1){ref-type="fig"}D). The electrostatic repulsion by the C20 2,2-dimethyl succinic acid side chain of KglA can also explain the inhibition of monophosphorylated pApUpC synthesis (which is allowed by RIF; [Figure 1](#fig1){ref-type="fig"}E).

A comparative analysis of the structures of the *E. coli* βS531L RNAP σ^70^ holoenzyme in apo form and in complex with RIF and KglA reveals the mechanism of KglA's efficiency against many RIF-resistant forms of mutant RNAPs ([Figure 2](#fig2){ref-type="fig"}F). The amino acid substitution βS531L is the most clinically important RIF-resistant mutation in bacterial RNAP because of its low structural and functional effects on the enzyme in the absence of RIF. As shown in a recent study ([@bib31]), RIF binding to the mutant RNAP results in a steric clash of the naphthalene core with the side chain of β531L, which triggers disordering of a constituent part of the RIF-binding pocket, the fork loop2 ([Figure 2](#fig2){ref-type="fig"}F, left versus right). This partial disordering of the RIF-binding site efficiently prevents RIF binding. The naphthalene core of KglA is almost identical to RIF; however, it is rotated in the binding site compared with RIF ([Figure 2](#fig2){ref-type="fig"}D). This positional shift allows KglA to maintain a distance to β531L, avoiding a severe clash with the residue and minimizing structural rearrangements of the fork loop2 and the binding pocket ([Figure 2](#fig2){ref-type="fig"}F, center). This fine-tuning of the core binding mode and the increased interaction surface provided by the C27 sugar side chain enable high affinity of KglA in a broad context of RIF resistance.

Kanglemycin A Has Antimicrobial Activity against MDR-*M. tuberculosis* and Other Gram-Positive Pathogens {#sec2.4}
--------------------------------------------------------------------------------------------------------

The above results suggested that KglA may be effective against RIF-resistant bacteria, in particular against clinically problematic MDR-*M. tuberculosis* strains. Thus, we tested KglA against a clinical MDR-*M. tuberculosis* isolate (Beijing 08/00483E) that is fully resistant to RIF ([@bib21], [@bib50]) and the other first-line antibiotics (isoniazid, ethambutol, and pyrazinamide). Beijing 08/00483E carries the most frequent RNAP amino acid change found in RIF-resistant *M. tuberculosis* (βS450L, *M. tuberculosis* numbering; βS531L, *E. coli* numbering; [Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D). As positive controls, we used the RIF-susceptible reference strain of *M. tuberculosis* H37Rv and a RIF-susceptible clinical isolate, Beijing 1192/015. The clinical strain Beijing 08/00483E was resistant to RIF at 1,024 times the minimum inhibitory concentration (MIC) for RIF-sensitive strains ([Figures 3](#fig3){ref-type="fig"}A and 3B). In contrast, all three strains displayed a dose-dependent response to KglA exposure ([Figure 3](#fig3){ref-type="fig"}A), demonstrating its antimicrobial activity against MDR-*M. tuberculosis*. KglA was statistically significantly more active against RIF-sensitive Beijing 1192/015 than RIF-resistant Beijing 08/00483E ([Figures 3](#fig3){ref-type="fig"}A and 3B).Figure 3KglA Inhibits Mycobacterial RNAP and Retains Antimicrobial Activity against MDR-*M. tuberculosis*(A) Dose-dependent growth inhibition of the RIF-susceptible *M. tuberculosis* strains H36Rv (black) and 1192/015 (red) and RIF-resistant *M. tuberculosis* 08/00483E (blue) by KglA (solid line, solid symbols) and RIF (dashed line, open symbols). Data presented are the mean of four independent experiments ± SD and analyzed using a Student's t test.(B) MIC values ± SD, as determined using the modified Gompertz function for *M. tuberculosis* strains H37Rv, 1192/015, and 08/00483E, which were exposed to RIF or KglA.(C) Mode of action of KglA and RIF against *M. smegmatis* RNAP. The experiment was performed exactly as in [Figure 1](#fig1){ref-type="fig"}D. Note that the high radioactive background compared with [Figure 1](#fig1){ref-type="fig"}D is due to much lower activity of *M. smegmatis* RNAP.(D) Inhibition of *M. smegmatis* RNAP by RIF and KglA.Error bars are ± SD. Shown in brackets are the IC~50~ values ± SE.

As seen in [Figures 3](#fig3){ref-type="fig"}A and 3B, RIF was more active against RIF-susceptible *M. tuberculosis* cells than KglA. This apparently contradicted our *in vitro* results of very similar inhibition of *E. coli* wild-type RNAP by both inhibitors. It is possible that the mode of inhibition of *M. tuberculosis* RNAP by KglA is different from that of *E. coli* RNAP. Therefore, we analyzed inhibition of transcription by *Mycobacterium smegmatis* RNAP, which is commonly used as an experimental model for *M. tuberculosis* RNAP. Both RNAPs have an identical amino acid composition of the RIF-binding pocket ([Figure S2](#mmc1){ref-type="supplementary-material"}C). We found that RIF and KglA inhibited RNA synthesis by *M. smegmatis* RNAP and *E. coli* RNAP in a very similar way (compare [Figure 1](#fig1){ref-type="fig"}D with [Figure 3](#fig3){ref-type="fig"}C); i.e., KglA fully blocked synthesis of the first dinucleotide (pppApU), whereas RIF partly allowed synthesis even of the trinucleotide (pppApUpC). The IC~50~ of KglA was nearly the same as that of RIF. Therefore, the affinity of RNAP binding cannot account for the observed difference in the activities of RIF and KglA against RIF-sensitive *M. tuberculosis* cells. The likely explanation of differences in activities of KglA and RIF against RIF-sensitive *M. tuberculosis* is the decreased ability of KglA to pass through the cell envelope.

We further tested KglA against a range of other species, including a number of clinically relevant pathogens. These included 8 Gram-positive bacteria, 10 Gram-negative bacteria, and 2 eukaryotes ([Table 2](#tbl2){ref-type="table"}). Of 10 Gram-negative pathogens, KglA was active against only *Providencia rettgeri*. No activity was observed toward the two strains of eukaryotic microorganisms (yeast): *Candida albicans* and *Candida glabrata*. Among the 8 Gram-positive strains, KglA was highly active (MIC, ∼1 μg/mL) against staphylococci and *Streptococcus pyogenes* but less active against enterococci (MIC, 64--128 μg/mL). The relatively high activity of KglA against staphylococci prompted evaluation of its activity against a large collection of methicillin-resistant *Staphylococcus aureus* (MRSA) and a comparison of its activity with RIF. *S. aureus* NCTC 6571 was re-tested as a control strain with a known MIC of RIF ([@bib15]). Thirty-seven MRSA were tested in total, and 33 of these proved to be susceptible to RIF, as defined by a MIC of ≤ 0.06 μg/mL ([@bib15]). KglA was substantially less active than RIF against RIF-susceptible MRSA, with MICs of KglA between 0.25 and 1 μg/mL. Conversely, for 3 of 4 RIF-resistant MRSA, MICs of KglA were 1--3 double dilutions lower than those of RIF, although still relatively high (32--128 μg/mL). In the light of our *in vitro* data ([Figures 1](#fig1){ref-type="fig"}C--1F and [3](#fig3){ref-type="fig"}C), no activity against most of Gram-negative bacteria, and lower-than-RIF activity against some Gram-positive bacteria support the idea of a diminished ability of KglA to enter bacterial cells. This, however, requires further investigation coupled with further *in vivo* analyses to develop KglA as a future antibiotic.Table 2MICs of KglA against Bacterial and Eukaryotic PathogensOrganism/IsolateStrain ReferenceKglA (μg/mL)RIF (μg/mL)Gram-Negative*Acinetobacter baumannii*ATCC 19606\>128--*Burkholderia cepacia*ATCC 25416\>128--*Enterobacter cloacae*NCTC 11936\>128--*Escherichia coli*NCTC 10418\>12816[a](#tblfn2){ref-type="table-fn"}*Klebsiella pneumoniae*NCTC 9528\>128--*Providencia rettgeri*NCTC 747564--*Pseudomonas aeruginosa*NCTC 10662\>128--*Salmonella enterica* TyphimuriumNCTC 74\>128--*Serratia marcescens*NCTC 10211\>128--*Yersinia enterocolitica*NCTC 11176\>128--Gram-Positive*Bacillus subtilis*NCTC 93721--*Enterococcus faecalis*NCTC 77564--*Enterococcus faecium*NCTC 7171128--*Listeria monocytogenes*NCTC 119948--*Staphylococcus epidermidis*NCTC 110471--*Staphylococcus aureus*NCTC 65710.250.004[a](#tblfn2){ref-type="table-fn"}*Staphylococcus aureus* (MRSA)NCTC 119391--*Streptococcus pyogenes*NCTC 83060.031--Yeast*Candida albicans*ATCC 90028\>128--*Candida glabrata*NCPF 9725\>128--*S. aureus*Bel9759722Bel9759864\>128Fin374810.5≤0.008Fin5451132\>128Fin54518128\>128Fra4620.5≤0.008Fra9201≤0.008Fra9503510.016Ger131/98 (Sger 11d2)0.50.016Ger1966/97 (Han 111c)0.5≤0.008Ger2594-1/97 (Sger 11a)10.016Ger2594-2/97 (Sger 11b)0.25≤0.008EMRSA 151729/980.5≤0.008EMRSA 151758/980.5≤0.008EMRSA 15149560.5≤0.008EMRSA 1512484/980.5≤0.008EMRSA 1514185/980.5≤0.008EMRSA 1516822/980.5≤0.008EMRSA 1519972/980.5≤0.008EMRSA 1520460/980.50.016EMRSA 1521268/980.5≤0.008EMRSA 1521698/980.5≤0.008EMRSA 152501/980.5≤0.008EMRSA 156323/980.5≤0.008EMRSA 1600036/9510.016EMRSA 1600998/951≤0.008EMRSA 1603732/9510.016EMRSA 1607121/951≤0.008EMRSA 1607924/950.5≤0.008EMRSA 1618200/950.5≤0.008EMRSA 1618205/950.5≤0.008EMRSA 1621354/9510.016EMRSA 1623728/981≤0.008EMRSA 1623729/981≤0.008EMRSA 1632010/9610.016EMRSA 1634256/961≤0.008MRSANCTC 119391≤0.008*Staphylococcus aureus*NCTC 65710.25≤0.008[^5]

Discussion {#sec3}
==========

Easily acquired RIF resistance is a major problem in the clinical usage of rifamycins. The principal finding of our study is that KglA is much more effective against RIF-resistant RNAPs and bacteria than its commonly used relative, RIF. The structural analysis suggests that this is explained by both additional interactions and the binding mode of KglA with RNAP unique to KglA. The sugar (β-*O*-3,4-*O*,*O*'-methylene digitoxose) and acid (2,2-dimethyl succinic acid) moieties at C27 and C20 of KglA, respectively, establish these additional contacts and influence the overall binding mode of KglA in the pocket ([Figures 2](#fig2){ref-type="fig"}C and 2D). Compared with RIF, KglA rotates to reposition slightly away (by 1.2 Å) from the wall of the binding pocket, which may decrease the effect of resistance mutations arising in RNAP on its affinity. Thus, the increased distance between the naphthalene core along with the increased binding surface provided by the *ansa*-bridge side chains likely represent the mechanisms that enable KglA to maintain its inhibitory activity against many RIF-resistant bacterial RNAPs. As the result of additional interactions by the sugar moiety with the protein, only an unlikely event of two simultaneous mutations in the RIF-binding pocket can lead to KglA resistance.

KglA inhibits RNA synthesis at the stage of the first phosphodiester bond (2-mer RNA) formation, which is different from RIF, which inhibits formation of the second phosphodiester bond (3-mer RNA) ([Figures 1](#fig1){ref-type="fig"}D and [2](#fig2){ref-type="fig"}E). Our biochemical and structural data suggest that this may happen because of the steric and/or electrostatic clash of the C20 2,2-dimethyl succinic acid side chain of KglA with γ and/or β phosphates of the +1 NTP that may disturb the conformation of initiating nucleotides and, thus, catalysis. We cannot directly compare these results with the previous study that found that some rifamycins may inhibit RNA synthesis one step earlier than RIF ([@bib5]) because they used a 5′ non-phosphorylated dinucleotide to start transcription. We, however, did not observe inhibition of 5′ non-phosphorylated trinucleotide synthesis by KglA ([Figure 1](#fig1){ref-type="fig"}C), as observed for some of the rifamycins in that study ([@bib5]), suggesting that inhibition of 5′ triphosphorylated dinucleotide synthesis by KglA takes place via a different mechanism.

KglA, compared with RIF, appears to show reduced penetration through the bacterial cell envelope, likely because of the presence of the polar carboxyl group at C20. For example, KglA has minimal activity against Gram-negative bacteria in comparison with RIF and displays higher MICs than RIF against most of the Gram-positive species tested. However, KglA is more effective than RIF against RIF-resistant Gram-positive bacteria. Notably, it is effective against MDR-*M. tuberculosis*. KglA inhibited the growth of MDR-*M. tuberculosis* (strain 08/00483E at a MIC of 0.854 μg/mL \[850.3 nM\]), which was completely resistant to RIF because of a βS450L substitution (βS531L in *E. coli* numbering). Finding new antibiotics for the treatment of MDR-TB is a challenge, and KglA demonstrates potential as a candidate for further development, particularly in light of the fact that the MIC of KglA is lower than the MIC values displayed for both isoniazid and pyrazinamide against drug-susceptible *M. tuberculosis*, and there is a wealth of information about drug toxicity and patient responses to RIF. These considerations are likely to accelerate the progression of KglA or its derivatives to the clinic for the treatment of both drug-susceptible and drug-resistant TB.

A new mode of KglA binding to RNAP may enrich the strategy of structure-guided antibiotic design against RIF-resistant pathogens such as MDR-*M. tuberculosis*. RIF resistance caused by a point mutation of the β subunit of RNAP is associated with either loss of important contact between a target and a compound (in the case of βS531L) or steric exclusion of a compound from its binding site (in the case of βH526Y) ([@bib31]). In many cases, research efforts focusing on developing new antibiotics targeting the RIF-resistant bacterial RNAP are searching for new interaction surfaces away from the RIF-binding pocket ([@bib27], [@bib28]). The enhanced affinity of KglA for certain RIF-resistant RNAPs along with the moderate changes in its mode of binding compared with RIF ([Figure 2](#fig2){ref-type="fig"}D) indicate that the RIF-binding pocket still possesses significant potential for the development of potent antibiotics against certain RIF-resistant pathogens. Targeting the RIF-binding pocket has some advantages compared with targeting a new site. For example, development of resistance to KglA is possible via additional mutations in the RIF-binding pocket (e.g., βR143A; [Figure S2](#mmc1){ref-type="supplementary-material"}E) in addition to the first RIF-resistant mutation (e.g., βS531L); however, such mutations may compromise the transcriptional integrity and further diminish the fitness of the RNAP, rendering the resulting pathogens non-viable ([@bib43]). Another important advantage of developing new rifamycin derivatives is that this approach exploits the well-known rifamycin scaffold and may likely overcome some obstacles common in the development of new antibiotics, such as the problems of drug permeability through bacterial membranes, human toxicity, and specificity ([@bib4]).

The modifications in the *ansa* bridge are highly unusual in bioactive rifamycins, with even minor semisynthetic modifications in an *ansa* bridge often leading to loss of RNAP inhibition (see [Introduction](#sec1){ref-type="sec"}). Our study reveals the significant potential of increasing the affinity of the rifamycins to RNAP via *ansa* bridge modifications, in particular by demonstrating that C27 substitution can allow access to a previously unexplored hydrophobic pocket adjacent to the RIF-binding pocket while maintaining the critical interactions between the rifamycin backbone and the RIF-binding pocket of RNAP. Furthermore, substitution at C20 with a flexible carboxylic acid residue has revealed the potential for new drug-initiating NTP interactions in the rifamycins. Altogether, KglA provides an example of an evolved solution to RIF resistance in which these unusual *ansa* bridge modifications lead to improved potency against RIF-resistant RNAPs and represents an important starting point for the development of new therapeutic agents.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Bacterial and Virus Strains***E. coli* BL21(DE3)NovagenCat\# 69450*M. smegmatis* mc^2^155 (SM07)[@bib32]N/A*Mycobacterium tuberculosis* H37Rv, Beijing 1192/015 and Beijing 08/00483EPHE National Mycobacterial Reference LaboratoryN/A*E. coli* T7 ExpressNew England BioLabsCat\# C2566H*B. subtilis* 168 *amyE*::*PhelD-lacZ cat*[@bib45]N/A*B. subtilis* 168 *amyE*::*PhelD-lacZ cat rpoB*~*H482R*~This paperN/A*Enterobacter cloacae*NCTCNCTC 11936*Escherichia coli*NCTCNCTC 10418*Klebsiella pneumoniae*NCTCNCTC 9528*Providencia rettgeri*NCTCNCTC 7475*Pseudomonas aeruginosa*NCTCNCTC 10662*Salmonella typhimurium*NCTCNCTC 74*Serratia marcescens*NCTCNCTC 10211*Yersinia enterocolitica*NCTCNCTC 11176*Bacillus subtilis*NCTCNCTC 9372*Enterococcus faecalis*NCTCNCTC 775*Enterococcus faecium*NCTCNCTC 7171*Listeria monocytogenes*NCTCNCTC 11994*Staphylococcus epidermidis*NCTCNCTC 11047*Staphylococcus aureus*NCTCNCTC 6571*Staphylococcus aureus* (MRSA)NCTCNCTC 11939*Streptococcus pyogenes*NCTCNCTC 8306*Candida glabrata*NCPFNCPF 9725*Acinetobacter baumannii*ATCCATCC 19606*Burkholderia cepacia*ATCCATCC 25416*Candida albicans*ATCCATCC 90028Clinical isolates of methicillin-resistant *Staphylococcus aureus* (MRSA) X 36.Public Heath England, Colindale, UKN/A*T. thermophilus* HB8ATCCATCC 27634**Chemicals, Peptides, and Recombinant Proteins**Ni-NTA agaroseQIAGENCat\# 30230HiTrap Q HP, 1 mLGE Healthcare Life SciencesCat\# 29051325HiLoad 26/600 Superdex 200GE Healthcare Life SciencesCat\# 28989336HiTrap Heparin HP, 5 mLGE Healthcare Life SciencesCat\# 17040601HisTrap HP, 5 mLGE Healthcare Life SciencesCat\# 17524801Bio-Rex 70 cation exchange resinBio-RadCat\# 1425842Biotage® SNAP Ultra 100 gBiotageCat\# FSUL-0442-0100\[alpha-P32\]Uridine 5′-triphosphate (UTP)Hartmann AnalyticCat\# SRP-810rNTP Set, 100 mM Solutions (ATP, CTP, GTP, UTP)GE HealthcareCat\# 27202501QuikChange II kit (Stratagene)AgilentCat\# 200523CpAIBA LifesciencesCat\# 5-0710-186RIFSigmaCat\# R3501Resazurin sodium saltSigmaCat\# R7017CMM MOD2[@bib20]N/AMiddlebrook 7H9 mediumBD DifcoCat\# 271310Phosphate buffered saline, pH 7.4Severn BiotechCat\# 20-74-10IsoSensitest agarOxoidCat\# CM0471Amberlite XAD-16SigmaCat\# XAD16**Deposited Data**KglA X-ray diffraction dataThis paperCCDC: 1827601 and 1827602*E. coli* RNAP -- KglA complexThis paperPDB: [6CUX](pdb:6CUX){#intref0010}*T. thermophilus* RNAP -- KglA complexThis paperPDB: [6CUU](pdb:6CUU){#intref0015}*E. coli* RNAP[@bib34]PDB: [4YG2](pdb:4YG2){#intref0020}*T. thermophilus* RNAP -- *pyrG* promoter complex[@bib35]PDB: [5VOI](pdb:5VOI){#intref0025}**Oligonucleotides**See Table S2 for list of oligonucleotides**Recombinant DNA**pVS10(S531L)[@bib17]N/ApGEMD[@bib34]N/ApET21a-SigA[@bib9]N/ApETLrpoB[@bib42]N/A**Software and Algorithms**COOT[@bib14]<https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/>HKL2000[@bib37]<http://www.hkl-xray.com>PHENIX[@bib1]<https://www.phenix-online.org>PymolPyMOL<https://pymol.org/2/>Graphpad 7.00Prism<https://www.graphpad.com/>SigmaPlot 11.0Systat Software<https://systatsoftware.com/>**Other**VDX48 Plate with sealantHampton ResearchCat\# HR3-27512 mm x 0.22 mm Siliconized circle cover slidesHampton ResearchCat\# HR3-27918 mm Mounted CryoLoop - 20 micronHampton ResearchCat\# HR4-973CrystalCap ALS with vialHampton ResearchCat\# HR4-779Vivaspin sample concentrator (MWCO 10 kDa)GE Healthcare Life SciencesCat\# 28-9323-60Tecan Sunrise microplate absorbance readerTecan instruments<https://www.tecan.com/>Infinite M1000 multimode plate readerTecan instruments<https://www.tecan.com/>Isolaera ONEBiotageCat\# ISO-1SWJeol Lambda 500 MHz spectrometerJEOL LtdN/AJeol ECS 400 MHz spectrometerJEOL LtdN/AGemini X-ray Diffractometer/Atlas detectorOxford DiffractionN/ABeam Station I19National Synchrotron Facility Diamond Light SourceN/A

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to Lead Contact (<n.zenkin@ncl.ac.uk>).

Method Details {#sec4.3}
--------------

### Disk diffusion assay {#sec4.3.1}

Standard disc diffusion assay (Kirby-Bauer) was performed with the *B. subtilis* 168 *amyE*::*P*~*helD*~*-lacZ cat* reporter strain or RIF-resistant *B. subtilis* 168 *rpoB*~*H482R*~ strain as described ([@bib10]). Briefly, disks were loaded with to 10 μg of each drug, air-dried and placed on nutrient agar plates with embedded lawn of bacteria and x-gal (100 μg/mL). Plates were incubated overnight at 37°C and scanned.

### Isolation of KglA from Amycolatopsis sp. DEM30355 {#sec4.3.2}

The fermentation of the *Amycolatiopsis* sp. DEM303555 was conducted as previously described. ([@bib24]). One kilogram of Amberlite XAD-16 resin was washed with deionized water and then applied to 50 L of filtered culture supernatant in batch absorption. The material was eluted with 32 L of 100% methanol and concentrated under reduced pressure (2.5 L). The concentrate was adjusted to pH 6.5 and extracted eight times with an equal amount of ethyl acetate. The organic extracts were combined and evaporated to dryness to yield 22.5 g of crude extract. A sample of the crude extract (3.91 g) was subjected to silica gel chromatography (eluent = 100% ethyl acetate, Biotage SNAP 100 g cartridge). KglA-containing fractions were combined and the solvent was removed under reduced pressure to give 1.24 g of a dark colored solid. This material was subjected to a second silica gel chromatography step (eluent = linear gradient from diethyl ether to ethyl acetate. Evaporation of the KglA containing fractions yielded 806.2 mg as an orange solid.

### Small molecule X-ray crystallography including absolute configuration of KglA {#sec4.3.3}

Slow evaporation of a methanol solution of KglA gave crystals suitable for single-crystal X-ray analysis. The molecular structure of KglA was obtained to high precision using synchrotron radiation with a very small crystal of the methanol solvate at 120 K; all H atoms were located and freely refined. The short X-ray wavelength of 0.6889 Angstroms did not permit the determination of the absolute configuration, which was subsequently established unambiguously with CuKalpha radiation and a larger crystal, giving a molecular structure with otherwise slightly lower precision. CCDC 1827601 and 1827602 contain the supplementary crystallographic data for this paper, these data can be obtained free of charge from The Cambridge Crystallographic Data Centre (<https://www.ccdc.cam.ac.uk/>).

### NMR analysis of KglA {#sec4.3.4}

All NMR spectra were recorded in CDCl~3~ at 10°C. ^1^H and ^13^C{^1^H} NMR spectra were recorded directly with a Jeol Lambda 500 MHz spectrometer (Figure S1), while ^1^H COSY; 45, 90 and 135 DEPT; HMQC and HMBC were recorded with a Jeol ECS 400 MHz spectrometer (not shown). Proton and carbon assignment was performed *de novo* from both 1D and 2D NMR experiments and was in close agreement with the literature ([@bib46], [Table S1](#mmc1){ref-type="supplementary-material"}).

### Purification of *E. coli* RNAP core enzyme and σ^70^, and ***M. smegmatis* RNAP holoenzyme** for transcription assays {#sec4.3.5}

RIF-resistant mutations were introduced in pETLRpoB plasmid (6xHis-tag on N terminus of β subunit of *E. coli* RNAP) ([@bib42]) by site-directed mutagenesis using QuikChange II kit (Stratagene). Wild-type or mutant plasmids were transformed along with pACYCDuet-1_Ec_rpoZ (encoding for ω subunit) in T7 Express strain (New England Biolabs). Expression and purification of core RNAP was performed as described ([@bib23]) (with heparin chromatography used instead of gel filtration as suggested). N-terminal 6xHis-tagged *E. coli* σ^70^ subunit was purified as described ([@bib48]).

Cellular *M. smegmatis* RNAP holoenzyme with 6xHis-tag on C terminus of β' subunit was purified as *E. coli* RNAP above from *M. smegmatis* mc^2^155 (SM07) ([@bib32]), with exception that cells were grown in MB-7H9 media supplemented with 0.05 Tween 80 and 2% glucose to late exponential phase.

### *In vitro* transcription {#sec4.3.6}

One pmol of wild-type or mutant *E. coli* RNAP core and 3 pmols of σ^70^ (or one pmol of *M. smegmatis* holoenzyme) and 0.1 pmols of linear template containing T7A1 promoter ([@bib22], [@bib39]) were mixed in 7 μL of transcription buffer (20 mM Tris HCl pH 7.9, 40 mM KCl, 10 mM MgCl~2~). 1 μL of DMSO containing or not containing antibiotics (concentrations specified in Figures) was added to the reaction. Transcription was initiated by the addition of 2 μL of the mixture of nucleotides in transcription buffer, containing (final concentrations): 25 μM CpA or 0.5 mM ATP or 5 mM AMP with different combinations or all of 100 μM ATP, CTP and GTP and 10 μM α-\[^32^P\]UTP (20 Ci/mmol) (Hartmann Analytic). Reactions were stopped after 10-min incubation at 37°C by the addition of formamide-containing loading buffer. Products were separated on 20% or 33% denaturing (8M urea) polyacrylamide gels, revealed by PhosphorImaging (GE Healthcare), and analyzed using ImageQuant software (GE Healthcare). Activities (a sum of run off and termination products) were normalized to the activity without antibiotic, which was taken as 100%. The average activity of at least three replicates for each concentration of antibiotic was plotted (with their standard deviations as error bars) against concentration and fitted in four parameter logistic equation by nonlinear regression using SigmaPlot. The averages and standard deviations of the three individual IC~50~s are reported in [Figure 1](#fig1){ref-type="fig"}E.

### Crystallization of RNAP -- KglA complexes {#sec4.3.7}

The βS531L RIF-resistant mutant *E. coli* RNAP σ^70^ holoenzyme was prepared and crystallized as previously described ([@bib31]). The complex of the *T. thermophilus* RNAP σ^A^ holoenzyme bound to *pyrG* promoter was prepared and crystallized as previously described ([@bib35]). To prepare complexes of RNAPs with KglA, the RNAP crystals were soaked overnight at 22°C in the respective cryoprotection solutions supplemented with 1 mM KglA. After the soaking, crystals were frozen by plunging to liquid N~2~.

### Crystallographic data collection and X-ray crystal structure determinations {#sec4.3.8}

The X-ray diffraction datasets were collected at the Macromolecular Diffraction at the Cornell High Energy Synchrotron Source (MacCHESS) F1 beamline (Cornell University, Ithaca, NY) and the data were processed by HKL2000 ([@bib37]). Structures were determined by molecular replacement using the structures of the *E. coli* RNAP ([@bib34]) and the *T. thermophilus* RNAP -- *pyrG* promoter complexes ([@bib35]) as corresponding initial search models. The structures were refined as the rigid body and the positional refinement with non-crystallographic symmetry and reference model structure restraints using the suite of programs Phenix ([@bib2]). The resulting electron density maps revealed clear maps corresponding to KglA that was not present in the initial search models, and the KglA model was fitted into the density maps using Coot ([@bib14]). The [Table 1](#tbl1){ref-type="table"} contains data collection and refinement statistics for the structures of the determined RNAP -- KglA complexes. The final coordinates and structure factors were deposited to the PDB with ID codes listed in [Table 1](#tbl1){ref-type="table"}.

### Determination of minimum inhibitory concentrations (MICs) for *M. tuberculosis* {#sec4.3.9}

#### Bacterial strains and reagents {#sec4.3.9.1}

*Mycobacterium tuberculosis* strains*:* H37Rv, Beijing 1192/015 and Beijing 08/00483E (multi-drug resistant, MDR) were used in the modified resazurin microtiter assay (REMA) plate method. Beijing strains 1192/015 and 08/00483E were obtained from the PHE National Mycobacterial Reference Laboratory. Beijing 08/00483E contains a single nucleotide polymorphism (SNP) at position 761155 of C→T, which has resulted in an amino acid change, S450L (corresponding to S531L with *E. coli* numbering), within the RIF-binding pocket. Beijing 08/00483E is also resistant to isoniazid, ethambutol, and pyrazinamide, through mutations in known resistance genes. Other reagents used were: Middlebrook 7H9 medium (BD Difco), OADC supplemented with 0.5% glycerol (24388.295, VWR Chemicals) and 0.2% Tween 80 (P1754, Sigma), CAMR Mycobacterium Medium MOD2 (CMM MOD2) ([@bib20]), RIF (PanReac AppliChem, cat no.A2220) and 0.02% resazurin solution (10 mg resazurin sodium salt (R7017, Sigma) in 50 mL phosphate buffered saline, pH 7.4 (Severn Biotech) containing 5% Tween 80) ([@bib18]). All the antibiotics were dissolved in methanol (322415, Sigma) to a stock concentration of 10 mg/mL.

#### Preparation of bacterial inocula {#sec4.3.9.2}

Bacterial strains were grown in 50 mL of OADC-supplemented, Middlebrook 7H9 medium with 0.5% glycerol and 0.2% Tween 80 in vented Erlenmeyer flasks, shaken at 37°C for 5 days. Inocula for the REMA method were prepared to an OD~540~ of 0.5, from Middlebrook 7H9 cultures by diluting cells in CMM MOD2 medium.

#### Modified resazurin microtiter assay (REMA) plate method {#sec4.3.9.3}

A modification of the REMA plate method previously described by ([@bib36]) was used. A 10 mg/mL stock solution of KglA was prepared in methanol (322415, Sigma). A two-fold serial dilution of the stock solution was performed in CMM MOD2 medium. 100 μl of each KglA concentration was added to six replicate wells in a 96-well untreated flat bottomed 96-well plate (734-1554, VWR). Three of the wells remained as "drug-only" wells and the other three wells were "test wells," which were used to test the activity of KglA. 10 μl of bacterial culture was added to the test wells to give a final OD~540~ of 0.05. Three further wells contained 100 μl of growth medium and 10 μl of bacterial cells as "zero-drug" controls to confirm exponential growth of the bacteria in the absence of antibiotic. The drug-only controls allowed for confirmation that there was an absence of colorimetric interference from the candidate antibiotic. Bacterial cell samples were diluted to an optical density (OD~540~) of 0.5 and 10 μl of the inoculum was added to each of the test wells and the zero drug controls. 10 μl of CMM MOD2 growth medium was added to the drug-only wells. The 96-well plates were incubated for 7 days at 37°C while shaking at 200 rpm. Drug activity was ascertained by adding 11 μl resazurin to every well of the 96 well-plate and incubating the plate at room temperature for 6 hours. The optical density (OD~570~) was measured for each well. The OD~570~ measurements were converted to a percentage of the zero-drug control so that data were expressed as a percentage of the growth without antibiotic.

#### Statistical analyses {#sec4.3.9.4}

The average OD~570~ for each drug concentration was fitted to a sigmoidal curve using the modified Gompertz function (*y* = A + Ce^-eB(*x*^ ^-\ M)^) and the minimum inhibitory concentration (MIC) was identified from the point of inflexion of the lower asymptote ([@bib25]). This was applied to the mean of the OD~570~ of four biological repeats to produce a graphical representation for each condition. An unpaired, two tailed, Students t test was used to determine significance between biological repeats.

### Determination of minimum inhibitory concentrations for other bacteria {#sec4.4.2}

MICs were determined using the agar dilution method specified by the British Society for Antimicrobial Chemotherapy against a collection of 56 isolates ([@bib3]). Briefly, KglA was initially dissolved in a minimal volume of dimethyl sulfoxide and diluted in water before incorporation into IsoSensitest agar (Oxoid) at a final concentration range of 128 -- 0.031 μg/mL. A final inoculum of 10 000 CFU/spot was used for inoculation of plates. Cultures were incubated for 22 hours at 37 ± 0.5°C. The MIC was recorded as the lowest concentration of KglA that achieved complete inhibition of visible growth. Inhibitor-free controls were also tested, including those containing equivalent solvent concentrations. All tests were performed at least twice on separate occasions to demonstrate reproducibility.

The collection included 16 isolates acquired from the National Collection of Type Cultures (NCTC; Colindale, UK), 3 isolates from the American Type Culture Collection (ATCC; Manassas, USA), and one from the National Collection of Pathogenic Fungi (NCPF; Colindale, UK). Also included were 36 strains of methicillin-resistant *Staphylococcus aureus* (MRSA) kindly supplied by Public Health England (Colindale, UK). These 36 strains were isolated from clinical samples in five European countries and included representatives of the major clones responsible for outbreaks of infection.

Data and Software Availability {#sec4.5}
------------------------------

The atomic coordinates and structure factors have been deposited in the Protein Data Bank, <https://www.pdb.org> (PDB ID codes 6CUX and 6CUU). CCDC 1827601 and 1827602 contain the supplementary crystallographic data for this paper, these data can be obtained free of charge from The Cambridge Crystallographic Data Centre (<https://www.ccdc.cam.ac.uk/>).
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